NYMC Faculty Publications
Everolimus for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Journal Title
Expert Opinion on Investigational Drugs
First Page
583
Last Page
592
Document Type
Article
Publication Date
July 2019
Department
Medicine
Abstract
Introduction: PDAC is a lethal malignancy with a clear unmet need; almost all patients fail 1(st), 2(nd), and 3(rd) line multi-agent cytotoxic chemotherapy. The mammalian target of rapamycin (mTOR) has been identified as a key signaling node enhancing tumor survival and drug resistance in PDAC; hence, it is considered a promising therapeutic target. Areas covered: We comprehensively reviewed the evidence from preclinical and phase I and II clinical trials, based on the authors'clinical experience and a PubMed, Cochrane library, Embase, and Google Scholar search everolimus + pancreatic cancer. Expert opinion: Everolimus has not demonstrated efficacy in PDAC; however, an mTOR inhibitor in combination with stroma-targeted therapies may be a promising area to explore in clinical trials.
Recommended Citation
Babiker, H., Karass, M., Recio-Boiles, A., Chandana, S., McBride, A., & Mahadevan, D. (2019). Everolimus for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma (PDAC). Expert Opinion on Investigational Drugs, 28 (7), 583-592. https://doi.org/10.1080/13543784.2019.1632289
